Leen Sas

Leen Sas

Auto-generated profile, based on publicly available information

Leen Sas

Translational Cancer Research Unit, Oncology Center, GZA hospitals St-Augustinus, Oosterveldlaan 24, 2610, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
LSLeen Sas
Leen Sas
FLFilip Lardon
Filip Lardon
PVPeter B Vermeulen
Peter B Vermeulen
JHJan Hauspy
Jan Hauspy
PDPeter Van Dam
Peter Van Dam
SLSteven J Van Laere
Steven J Van Laere
Endocrine therapy is a commonly used treatment for estrogen receptor (ER)-positive breast cancer. Although endocrine therapy has a favorable outcome in many patients, development of resistance is common. Recent studies have shown that NFκB, a transcription factor regulating a wide variety of cellular processes, might play a role in the development of endocrine resistance. The precise interaction between ER and NFκB and how this contributes to the attenuated responsiveness of ER-positive breast cancer cells to hormonal treatment remains unclear. This review provides an overview of the mechanisms of action for both transcription factors and focuses on the current knowledge explaining how ER and NFκB affect each other's activity and how this cross-talk might contribute to the development of an endocrine resistance phenotype in breast cancer cells.